Mary Erickson

2.5k total citations · 1 hit paper
13 papers, 2.0k citations indexed

About

Mary Erickson is a scholar working on Epidemiology, Hepatology and Surgery. According to data from OpenAlex, Mary Erickson has authored 13 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Epidemiology, 6 papers in Hepatology and 4 papers in Surgery. Recurrent topics in Mary Erickson's work include Liver Disease Diagnosis and Treatment (7 papers), Liver Diseases and Immunity (4 papers) and Liver Disease and Transplantation (3 papers). Mary Erickson is often cited by papers focused on Liver Disease Diagnosis and Treatment (7 papers), Liver Diseases and Immunity (4 papers) and Liver Disease and Transplantation (3 papers). Mary Erickson collaborates with scholars based in United States, Denmark and Belgium. Mary Erickson's co-authors include Sandrine Javorschi, Tsu‐Shuen Tsao, Bernard E. Bihain, Harvey F. Lodish, Frances T. Yen, Joachim Fruebis, Jonathan D. Roth, David G. Parkes, Brent A. Neuschwander‐Tetri and Elizabeth M. Brunt and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Hepatology.

In The Last Decade

Mary Erickson

12 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice

2001 1.6k citations Joachim Fruebis, Tsu‐Shuen Tsao et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mary Erickson United States	9	1.5k	1.0k	479	455	320	13	2.0k
John P. Chamberland United States	30	843 0.6×	868 0.9×	651 1.4×	433 1.0×	332 1.0×	49	2.3k
Kristina Wallenius Sweden	19	919 0.6×	989 1.0×	455 0.9×	582 1.3×	443 1.4×	37	2.2k
Miki Okada‐Iwabu Japan	18	921 0.6×	731 0.7×	244 0.5×	649 1.4×	183 0.6×	29	1.8k
Todd Schraw United States	13	1.3k 0.9×	1.2k 1.1×	320 0.7×	650 1.4×	274 0.9×	16	2.4k
Marek Strączkowski Poland	26	815 0.5×	927 0.9×	288 0.6×	827 1.8×	355 1.1×	76	2.4k
Masato Iwabu Japan	21	944 0.6×	727 0.7×	200 0.4×	637 1.4×	189 0.6×	37	2.0k
Naoki Furuyama Japan	10	1.9k 1.2×	1.3k 1.2×	553 1.2×	726 1.6×	401 1.3×	13	2.8k
Yusuke Hada Japan	8	1.4k 0.9×	883 0.9×	343 0.7×	428 0.9×	124 0.4×	8	1.7k
Carl de Luca United States	9	858 0.6×	864 0.9×	619 1.3×	541 1.2×	244 0.8×	9	2.1k
Agnieszka Nikołajuk Poland	25	629 0.4×	768 0.8×	241 0.5×	630 1.4×	325 1.0×	89	2.1k

Countries citing papers authored by Mary Erickson

Since Specialization

Citations

This map shows the geographic impact of Mary Erickson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Erickson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Erickson more than expected).

Fields of papers citing papers by Mary Erickson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Erickson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Erickson. The network helps show where Mary Erickson may publish in the future.

Co-authorship network of co-authors of Mary Erickson

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Erickson. A scholar is included among the top collaborators of Mary Erickson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Erickson. Mary Erickson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Alkhouri, Naim, Jeffrey E. Edwards, Fred Poordad, et al.. (2024). Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH. Liver International. 44(4). 966–978. 10 indexed citations

Adorini, Luciano, Kristoffer Rigbolt, Michael Feigh, Jonathan D. Roth, & Mary Erickson. (2024). Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis. PLoS ONE. 19(4). e0300809–e0300809. 6 indexed citations

Ramachandran, Prakash, Madara Brice, Anna M. Hoy, et al.. (2024). Aberrant basement membrane production by HSCs in MASLD is attenuated by the bile acid analog INT-767. Hepatology Communications. 8(12). 1 indexed citations

Carr, Rotonya M., Yun Li, Lillian Chau, et al.. (2023). An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations. Hepatology. 78(6). 1843–1857. 16 indexed citations

Bonder, Alan, et al.. (2023). Modulation of alkaline phosphatase levels by obeticholic acid in clinical trials and cultured human hepatocytes. Journal of Hepatology. 78. S378–S378. 1 indexed citations

Zhao, Xin, et al.. (2022). Maternal immune activation accelerates puberty initiation and alters mechanical allodynia in male and female C57BL6/J mice. Developmental Psychobiology. 64(5). e22278–e22278. 9 indexed citations

Zhao, Xin, et al.. (2021). Poly (I:C)-induced maternal immune activation modifies ventral hippocampal regulation of stress reactivity: prevention by environmental enrichment. Brain Behavior and Immunity. 95. 203–215. 31 indexed citations

Frisch, Kim, Michael Sørensen, Ole Lajord Munk, et al.. (2020). Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis. Journal of Hepatology. 74(1). 58–65. 62 indexed citations

Veidal, Sanne Skovgård, Christina Christoffersen, Michael Feigh, et al.. (2019). Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH. BMC Gastroenterology. 19(1). 228–228. 12 indexed citations

10.

Bowlus, Christopher L., Elizabeth J. Carey, George R. DeMuth, et al.. (2018). Primary biliary cholangitis (PBC) in the U.S.: real world effectiveness of obeticholic acid in TARGET-PBC. Journal of Hepatology. 68. S228–S229.

11.

Trevaskis, James L., Peter S. Griffin, Carrie Wittmer, et al.. (2012). Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. American Journal of Physiology-Gastrointestinal and Liver Physiology. 302(8). G762–G772. 220 indexed citations

12.

Roth, Jonathan D., Mary Erickson, Steve Chen, & David G. Parkes. (2011). GLP‐1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities. British Journal of Pharmacology. 166(1). 121–136. 59 indexed citations

13.

Fruebis, Joachim, Tsu‐Shuen Tsao, Sandrine Javorschi, et al.. (2001). Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proceedings of the National Academy of Sciences. 98(4). 2005–2010. 1606 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact